One of the leading health conditions facing today’s society is acute pain. This type of pain can result from most any situation including sprains and strains, all the way to trauma requiring surgery in outpatient and hospital settings.
Charleston Laboratories’ lead drug in its pipeline of acute pain treatments, CL-108, is in development for moderate-to-severe pain that requires an opioid analgesic, while preventing or reducing Opioid-Induced Nausea and Vomiting (OINV).
CL-108 is a novel bi-layered tablet with a bi-phasic release of 12.5 mg of rapid release promethazine with a modified release of 7.5 mg of hydrocodone and 325 mg of acetaminophen.View Entire Pipeline
Pain affects more Americans than diabetes, heart disease, and cancer combined.1
Immediate-release opioids are the most common prescription drug treatment for acute pain, including combination products containing hydrocodone and acetaminophen. However, these treatments come with side effects of nausea and vomiting. These side effects may prevent patients from appropriately taking drug treatment for their pain, which may inhibit their chances of a timely and smooth recovery.
Pain is cited as the most common reason Americans access the healthcare system.1
There is an unmet need for pain products with fewer side effects, which is why Charleston Laboratories is dedicated to developing novel opioid analgesics that prevent or reduce Opioid-Induced Nausea and Vomiting (OINV).
Approximately 76.2 million, one in every four Americans, have suffered from pain that lasts longer than 24 hours.1
Charleston Laboratories’ lead drug in its pipeline of acute pain treatments, CL-108, is specifically designed to provide both pain relief and prevention or reduction of nausea and vomiting for patients requiring opioid therapy.Learn More
Reference: 1. National Institutes of Health. Fact Sheets: Pain Management. http://report.nih.gov/nihfactsheets/ViewFactSheet.aspx?csid=57. Accessed June 8, 2017.